Lilly ramps up Indiana manufacturing with $4.5B push, opens first dedicated genetic medicine facility

Eli Lilly announced a further $4.5 billion in Indiana manufacturing investments across two Lebanon, Ind., sites — Lebanon API and its first dedicated genetic medicine facility, Lebanon Advanced Therapies — bringing total Indiana commitments since 2020 to over $21 billion. The Lebanon campus will include API, Advanced Therapies, and a Foundry, with the site expansion supporting current and future medicines (including Zepbound and Mounjaro) and products like Foundayo and retatrutide. The company says Lebanon API is slated to become the largest U.S. API production site when it opens in 2027, underscoring Lilly’s broader domestic manufacturing expansion and economic impact.